Kendra Adams - Sep 18, 2023 Form 3 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role
Chief Financial Officer
Signature
/s/ Jolie M. Siegel, Attorney-in-Fact
Stock symbol
CCCC
Transactions as of
Sep 18, 2023
Transactions value $
$0
Form type
3
Date filed
9/19/2023, 07:20 PM
Next filing
Feb 15, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CCCC Common Stock 21.6K Sep 18, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CCCC Stock Option (Right to Buy) Sep 18, 2023 Common Stock 57.4K $19.00 Direct F2
holding CCCC Stock Option (Right to Buy) Sep 18, 2023 Common Stock 45K $22.71 Direct F3
holding CCCC Stock Option (Right to Buy) Sep 18, 2023 Common Stock 75K $5.67 Direct F4
holding CCCC Performance Restricted Stock Units Sep 18, 2023 Common Stock 16.5K Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes a grant of 15,000 restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs vest in four equal annual installments, with the first installment vesting on February 13, 2024, subject to the Reporting Person's continued service on each vesting date.
F2 Represents underlying unexercised stock options that were granted on November 9, 2020. The terms of the original grant provide that 25% of this option vested and became exercisable on November 9, 2021, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service on each vesting date.
F3 This option vests and becomes exercisable in sixteen equal quarterly installments, with the first installment vested on May 14, 2022, subject to the Reporting Person's continued service on each vesting date.
F4 This option vests and becomes exercisable in sixteen equal quarterly installments, with the first installment vested on May 13, 2023, subject to the Reporting Person's continued service on each vesting date.
F5 Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones.

Remarks:

Exhibit 24 - Power of Attorney